Literature DB >> 19444763

Hearing Impairment in 2008: a compilation of available epidemiological studies.

Donatella Pascolini1, Andrew Smith.   

Abstract

A data bank of prevalence of hearing impairment for monitoring and implementation of programmes at national or global level and for the estimate of the global burden has been established. A systematic search was conducted of random-sample population-based studies of bilateral hearing impairment with clearly defined hearing threshold levels. Fifty-three studies from 31 countries from all WHO regions were found to meet the selection criteria. The prevalence of mild and disabling hearing impairment and other details from the studies are reported by WHO region. Although a large number of studies were found, only a small number among them were suitable surveys of prevalence of bilateral hearing impairment in the general population. Hearing impairment is a major disability that should be monitored at all ages: more population-based surveys are needed in all regions of the world. Utilization of the WHO protocol is recommended for collection and analysis of data in standard ways; especially recommended is the use of WHO threshold levels and to report the prevalence of bilateral impairment, both of which required to calculate burden.

Entities:  

Mesh:

Year:  2009        PMID: 19444763     DOI: 10.1080/14992020902803120

Source DB:  PubMed          Journal:  Int J Audiol        ISSN: 1499-2027            Impact factor:   2.117


  18 in total

1.  Evidence of hearing loss in a 'normally-hearing' college-student population.

Authors:  C G Le Prell; B N Hensley; K C M Campbell; J W Hall; K Guire
Journal:  Int J Audiol       Date:  2011-03       Impact factor: 2.117

2.  PMM2-CDG and sensorineural hearing loss.

Authors:  Çiğdem Seher Kasapkara; Zeren Barış; Mustafa Kılıç; Deniz Yüksel; Lies Keldermans; Gert Matthijs; Jaak Jaeken
Journal:  J Inherit Metab Dis       Date:  2017-07-31       Impact factor: 4.982

3.  Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.

Authors:  Annerose Keilmann; Todsaporn Nakarat; Iain A Bruce; David Molter; Gunilla Malm
Journal:  J Inherit Metab Dis       Date:  2011-08-25       Impact factor: 4.982

4.  The Hunter syndrome-functional outcomes for clinical understanding scale (HS-FOCUS) questionnaire: evaluation of measurement properties.

Authors:  Ingela Wiklund; Mireia Raluy-Callado; Donald E Stull; Yvonne Jangelind; David A H Whiteman; Wen-Hung Chen
Journal:  Qual Life Res       Date:  2012-05-19       Impact factor: 4.147

5.  Prevalence of Hearing Impairment by Age: 2nd to 10th Decades of Life.

Authors:  Koichiro Wasano; Takashi Nakagawa; Kaoru Ogawa
Journal:  Biomedicines       Date:  2022-06-17

6.  MMP-9 gene ablation mitigates hyperhomocystenemia-induced cognition and hearing dysfunction.

Authors:  Seema Bhargava; Sathnur Pushpakumar; Naira Metreveli; Srikanth Givvimani; Suresh C Tyagi
Journal:  Mol Biol Rep       Date:  2014-08       Impact factor: 2.316

Review 7.  Genetics of hearing loss in Africans: use of next generation sequencing is the best way forward.

Authors:  Kamogelo Lebeko; Jason Bosch; Jean Jacques Nzeale Noubiap; Collet Dandara; Ambroise Wonkam
Journal:  Pan Afr Med J       Date:  2015-04-17

8.  The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life.

Authors:  Mireia Raluy-Callado; Wen-Hung Chen; David A H Whiteman; Juanzhi Fang; Ingela Wiklund
Journal:  Orphanet J Rare Dis       Date:  2013-07-10       Impact factor: 4.123

9.  Cardiovascular risk factors and hearing loss among adults in a tertiary center of Northwestern Nigeria.

Authors:  Stephen Semen Yikawe; Kufre Robert Iseh; Anas Ahmad Sabir; Mfon Ime Inoh; Joseph Hassan Solomon; Nasiru Aliyu
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2017-08-18

Review 10.  Evidence for an Association Between Hearing Impairment and Disrupted Sleep: Scoping Review.

Authors:  Nathan A Clarke; Derek J Hoare; Edward C Killan
Journal:  Am J Audiol       Date:  2019-10-17       Impact factor: 1.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.